Manatt’s Ian Spatz, a senior advisor with Manatt Health, was quoted by ThinkProgress for an article on President Trump’s alternative to Medicare drug negotiations.
A concern about the president’s new plan to lower the cost of prescription spending is that it calls to merge some Medicare Part B drugs into Part D.
“One of the issues, especially for cancer drugs, is that oncologists often have to use many of them on a patient. They don’t have the luxury of saying, ‘These two are equivalent; we’ll use one instead of the other,’” said Spatz.
Read the article here.